Bank of New York Mellon’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-186,823
| Closed | -$11.2M | – | 4253 |
|
|
2019
Q4 | $11.2M | Buy |
186,823
+8,274
| +5% | +$311K | ﹤0.01% | 1908 |
|
|
2019
Q3 | $5.01M | Buy |
178,549
+12,108
| +7% | +$413K | ﹤0.01% | 2277 |
|
|
2019
Q2 | $6.3M | Buy |
166,441
+7,508
| +5% | +$288K | ﹤0.01% | 2213 |
|
|
2019
Q1 | $6.2M | Buy |
158,933
+6,701
| +4% | +$192K | ﹤0.01% | 2228 |
|
|
2018
Q4 | $3.25M | Buy |
152,232
+24,462
| +19% | +$631K | ﹤0.01% | 2506 |
|
|
2018
Q3 | $5.06M | Buy |
127,770
+77
| +0.1% | +$2.87K | ﹤0.01% | 2406 |
|
|
2018
Q2 | $4.88M | Buy |
127,693
+31,048
| +32% | +$1.15M | ﹤0.01% | 2400 |
|
|
2018
Q1 | $2.9M | Buy |
96,645
+14,236
| +17% | +$482K | ﹤0.01% | 2620 |
|
|
2017
Q4 | $2.58M | Buy |
82,409
+27,687
| +51% | +$760K | ﹤0.01% | 2706 |
|
|
2017
Q3 | $1.53M | Buy |
54,722
+1,822
| +3% | +$39.6K | ﹤0.01% | 2987 |
|
|
2017
Q2 | $1.01M | Buy |
52,900
+34,057
| +181% | +$544K | ﹤0.01% | 3244 |
|
|
2017
Q1 | $321K | Buy |
18,843
+5,009
| +36% | +$81K | ﹤0.01% | 3730 |
|
|
2016
Q4 | $253K | Buy |
+13,834
| New | +$239K | ﹤0.01% | 3827 |
|
Bank of New York Mellon's BOLD Position: Q1 2020 in Review
Bank of New York Mellon sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 186,823 shares — an estimated $11.2M sold.
Bank of New York Mellon first reported a position in BOLD in Q4 2016 and held it in 13 quarters. The position peaked at $11.2M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Bank of New York Mellon reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Bank of New York Mellon sold 186,823 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $11.2M.
- Bank of New York Mellon first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 13 quarters.
- Bank of New York Mellon's Audentes Therapeutics, Inc position peaked at $11.2M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Bank of New York Mellon's 13F filing for Q1 2020, filed 6 May 2020.